AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22463596 — intervention group
Group type: EXPERIMENTAL
Intervention: Good adherence (never missed pills in the last month)
Number of subjects: 2960
Study 22463596 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Drug Possession Ratio (DPR) throughout the first year
Number of subjects: 2960
Study 22463596 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor adherence (self-reported measures)
Number of subjects: 2960
Study 22463596 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor adherence subgroup by Markov Chain (MC)
Number of subjects: 2960
Study 22463596 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor adherence subgroup by Drug Possession Ratio (DPR)
Number of subjects: 2960
Study 20674286 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 14
Study 20674286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19256286 — intervention group
Group type: EXPERIMENTAL
Intervention: No Smoking is a Norm programme
Number of subjects: 1423
Study 19256286 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1423
Study 16167789 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (0.05 microg x kg(‐1) x min(‐1) administered intravenously during surgery)
Number of subjects: 30
Study 16167789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1 administration)
Number of subjects: 30
Study 12800126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-replacement therapy
Number of subjects: 0
Study 12800126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 0
Study 12800126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-replacement therapy and bupropion
Number of subjects: 0
Study 10992178 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative administration of low-dose cyclic oral contraceptives for 6 months
Number of subjects: 70
Study 10992178 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 70
Study 8833056 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (MTX 5/50-7.5/100 mg/week/day)
Number of subjects: 209
Study 8833056 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA 50-150 mg/day)
Number of subjects: 209
Study 8833056 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX 5-15 mg/week)
Number of subjects: 209
Study 8833056 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 209
Study 8833056 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment and AZA
Number of subjects: 209
Study 1459383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises for stress incontinence and bladder training for urge incontinence
Number of subjects: 110
Study 1459383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for first 3 months)
Number of subjects: 110
Study 1459383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises for stress incontinence and bladder training for urge incontinence (after initial control period)
Number of subjects: 110
Study 6147300 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blockade
Number of subjects: 0
Study 6147300 — intervention group
Group type: COMPARATOR
Intervention: No beta-adrenoceptor blockade (Control)
Number of subjects: 0
Study 29855682 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional core decompression (CD)
Number of subjects: 453
Study 29855682 — intervention group
Group type: EXPERIMENTAL
Intervention: CD combining bone grafting (BG)
Number of subjects: 453
Study 29855682 — intervention group
Group type: EXPERIMENTAL
Intervention: CD combining bone marrow mononuclear cells (BMMC)
Number of subjects: 453
Study 29855682 — intervention group
Group type: EXPERIMENTAL
Intervention: CD combining BG and BMMC
Number of subjects: 453
Study 29855682 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 453
Study 28714081 — intervention group
Group type: EXPERIMENTAL
Intervention: High positive schizotypes after sleep deprivation
Number of subjects: 36
Study 28714081 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprivation
Number of subjects: 36
Study 26184697 — intervention group
Group type: EXPERIMENTAL
Intervention: Group native airway, nonintubated, propofol (NA)
Number of subjects: 179
Study 26184697 — intervention group
Group type: COMPARATOR
Intervention: Group intubated, sevoflurane (IS)
Number of subjects: 179
Study 26184697 — intervention group
Group type: COMPARATOR
Intervention: Group intubated, propofol (IP)
Number of subjects: 179
Study 23175563 — intervention group
Group type: EXPERIMENTAL
Intervention: DHP + primaquine (0.75 mg/kg single dose on day 3)
Number of subjects: 349
Study 23175563 — intervention group
Group type: COMPARATOR
Intervention: DHP only
Number of subjects: 349
Study 21244169 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine consumption (amount not specified)
Number of subjects: 0
Study 21244169 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing in the afternoon
Number of subjects: 0
Study 21244169 — intervention group
Group type: COMPARATOR
Intervention: Testing in the morning
Number of subjects: 0
Study 21244169 — intervention group
Group type: EXPERIMENTAL
Intervention: Diurnal variation
Number of subjects: 0
Study 18433844 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg/day for 5 days)
Number of subjects: 6
Study 18433844 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/day for 5 days)
Number of subjects: 6
Study 18433844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 16769523 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practice (EBP) model
Number of subjects: 0
Study 16769523 — intervention group
Group type: EXPERIMENTAL
Intervention: EBP model
Number of subjects: 0
Study 14677161 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT) + stretching exercises
Number of subjects: 62
Study 14677161 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises alone
Number of subjects: 62
Study 11100000 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 60
Study 11100000 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 60
Study 11100000 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 8775351 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise (treadmill)
Number of subjects: 10
Study 1727902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 2',3'-dideoxyinosine (ddI)
Number of subjects: 48
Study 1727902 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 2',3'-dideoxyinosine (ddI)
Number of subjects: 48
Study 1727902 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ddI concentration
Number of subjects: 48
Study 6724661 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein supplement (58 g/day of a 60:40 mixture of soy and wheat proteins)
Number of subjects: 18
Study 6724661 — intervention group
Group type: COMPARATOR
Intervention: Low protein supplement (7 g/day of rice protein)
Number of subjects: 18
Study 30099542 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair-use prompts (signs)
Number of subjects: 13544
Study 30099542 — intervention group
Group type: COMPARATOR
Intervention: No signs (control)
Number of subjects: 13544
Study 29389170 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg/day
Number of subjects: 55
Study 29389170 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 2 mg/day
Number of subjects: 55
Study 29389170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 26551600 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-infant psychoanalytic treatment (MIP) group
Number of subjects: 80
Study 26551600 — intervention group
Group type: COMPARATOR
Intervention: Child Health Center care (CHCC) group
Number of subjects: 80
Study 24307655 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 1000000
Study 24307655 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzbromarone
Number of subjects: 1000000
Study 24307655 — intervention group
Group type: COMPARATOR
Intervention: Probenecid
Number of subjects: 1000000
Study 24307655 — intervention group
Group type: COMPARATOR
Intervention: Sulfinpyrazone
Number of subjects: 1000000
Study 22445769 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned stimulus (CS+) reinforced by electrical stimulation (US)
Number of subjects: 0
Study 22445769 — intervention group
Group type: COMPARATOR
Intervention: Control stimulus (CS-) that was never reinforced
Number of subjects: 0
Study 19720342 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal drug (500 mg of saffron, celery seed, and anise extracts three times a day for three days)
Number of subjects: 180
Study 19720342 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 180
Study 19720342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 17596273 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulisation of rhDNase before bedtime
Number of subjects: 24
Study 17596273 — intervention group
Group type: COMPARATOR
Intervention: Nebulisation of rhDNase after waking up
Number of subjects: 24
Study 15213023 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 9
Study 15213023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 12577351 — intervention group
Group type: EXPERIMENTAL
Intervention: 84.5% ginsenoside retention enema for 4‐6 hrs every day, 6‐8 days consecutively before surgical operation
Number of subjects: 50
Study 12577351 — intervention group
Group type: COMPARATOR
Intervention: Normal saline retention enema for 4‐6 hrs every day, 6‐8 days consecutively before surgical operation
Number of subjects: 50
Study 12577351 — intervention group
Group type: EXPERIMENTAL
Intervention: 84.5% ginsenoside retention enema
Number of subjects: 50
Study 12577351 — intervention group
Group type: COMPARATOR
Intervention: Normal saline retention enema
Number of subjects: 50
Study 9530843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load conditions with attention-demanding tasks
Number of subjects: 0
Study 9530843 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load conditions with attention-demanding tasks
Number of subjects: 0
Study 9530843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load manipulation of a visuospatial task requiring performance monitoring
Number of subjects: 0
Study 9530843 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial task with little monitoring
Number of subjects: 0
Study 9530843 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory suppression with different loads
Number of subjects: 0
Study 8788323 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT plus structured meal plans and grocery lists
Number of subjects: 163
Study 8788323 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT plus meal plans plus food provision (shared cost)
Number of subjects: 163
Study 8788323 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT plus meal plans plus free food provision
Number of subjects: 163
Study 8788323 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral treatment program (SBT)
Number of subjects: 163
Study 2076403 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 7350310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose electrolyte oral solution
Number of subjects: 111
Study 7350310 — intervention group
Group type: COMPARATOR
Intervention: Glucose electrolyte oral solution
Number of subjects: 111
Study 30755381 — intervention group
Group type: EXPERIMENTAL
Intervention: IA‐TXA (15 mg/kg)
Number of subjects: 228
Study 30755381 — intervention group
Group type: EXPERIMENTAL
Intervention: IV‐TXA (10 mg/kg)
Number of subjects: 228
Study 30755381 — intervention group
Group type: EXPERIMENTAL
Intervention: IA‐TXA (15 mg/kg) and IV‐TXA (10 mg/kg)
Number of subjects: 228
Study 30755381 — intervention group
Group type: COMPARATOR
Intervention: No‐TXA
Number of subjects: 228
Study 27002859 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention comprising four campaigns focused on gender and violence against women, alcoholism, sexual and reproductive health, and HIV/AIDS; implemented over 10 months with various interactive methods.
Number of subjects: 835
Study 27002859 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group (no specific intervention details provided).
Number of subjects: 835
Study 23582675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of darbepoetin-alpha (DA) 150 μg
Number of subjects: 56
Study 23582675 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 56
Study 21830967 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide 145 μg
Number of subjects: 1276
Study 21830967 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide 290 μg
Number of subjects: 1276
Study 21830967 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1276
Study 21830967 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide (both doses)
Number of subjects: 1276
Study 19207722 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine tablet
Number of subjects: 15
Study 17115870 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sessions of rapid smoking plus counseling
Number of subjects: 67
Study 17115870 — intervention group
Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 67
Study 15178988 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 0
Study 15178988 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 15178988 — intervention group
Group type: EXPERIMENTAL
Intervention: New stents and delivery systems
Number of subjects: 0
Study 11370797 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50-100 mg/day) for 12 weeks
Number of subjects: 82
Study 9198730 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (dF) 15 mg bid
Number of subjects: 103
Study 9198730 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (dF)
Number of subjects: 103
Study 9198730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 8458924 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol valerate 6 mg per os daily + intravaginal micronized progesterone 600 mg daily
Number of subjects: 378
Study 8458924 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal micronized progesterone 600 mg daily
Number of subjects: 378
Study 3007984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cytomegalovirus immune globulin and seronegative blood products
Number of subjects: 97
Study 3007984 — intervention group
Group type: EXPERIMENTAL
Intervention: Seronegative blood products alone
Number of subjects: 97
Study 3007984 — intervention group
Group type: EXPERIMENTAL
Intervention: Globulin alone
Number of subjects: 97
Study 3007984 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither treatment
Number of subjects: 97
Study 3007984 — intervention group
Group type: COMPARATOR
Intervention: Seronegative blood products
Number of subjects: 97
Study 3007984 — intervention group
Group type: COMPARATOR
Intervention: Standard blood products
Number of subjects: 97
Study 30590410 — intervention group
Group type: EXPERIMENTAL
Intervention: mAHTPred (meta-predictor using ensemble learning of four ML algorithms)
Number of subjects: 0
Study 30590410 — intervention group
Group type: COMPARATOR
Intervention: Baseline predictors (ERT-based models)
Number of subjects: 0
Study 29900829 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative TNFi
Number of subjects: 149
Study 29900829 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 149
Study 29900829 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 149
Study 29900829 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 149
Study 26420772 — intervention group
Group type: EXPERIMENTAL
Intervention: WIN (group A)
Number of subjects: 630
Study 26420772 — intervention group
Group type: COMPARATOR
Intervention: Incognito (group B)
Number of subjects: 630
Study 24784763 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF (Tenofovir disoproxil fumarate)
Number of subjects: 4747
Study 24784763 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF (Tenofovir disoproxil fumarate with Emtricitabine)
Number of subjects: 4747
Study 24784763 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 4747
Study 24784763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases (HIV seroconverters)
Number of subjects: 4747
Study 22675968 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium suppositories (100 mg/day)
Number of subjects: 70
Study 22675968 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin suppositories (100 mg/day)
Number of subjects: 70
Study 20099281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in Alu
Number of subjects: 723
Study 20099281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1
Number of subjects: 723
Study 20099281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in Alu among those aged 70 or older
Number of subjects: 723
Study 20099281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1 among individuals with a family history of cancer
Number of subjects: 723
Study 20099281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1 among current alcohol drinkers
Number of subjects: 723
Study 20099281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1 among current smokers
Number of subjects: 723
Study 20099281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1 among those who rarely or never consumed fruit
Number of subjects: 723
Study 20099281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1 among CC carriers for the MTRR Ex5+123C>T polymorphism
Number of subjects: 723
Study 20099281 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest level of methylation in LINE‐1 among TT carriers for the MTRR Ex15+572T>C polymorphism
Number of subjects: 723
Study 17509235 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone (200 mg single dose)
Number of subjects: 30
Study 17509235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15691257 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical nevi (AN)
Number of subjects: 459
Study 15691257 — intervention group
Group type: COMPARATOR
Intervention: Clearly benign nevi (BN)
Number of subjects: 459
Study 15691257 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma (MM)
Number of subjects: 459
Study 12060479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.05%
Number of subjects: 20
Study 12060479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1%
Number of subjects: 20
Study 12060479 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of tazarotene and mometasone furoate
Number of subjects: 20
Study 12060479 — intervention group
Group type: COMPARATOR
Intervention: All topical therapy regimens
Number of subjects: 20
Study 12060479 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with skin type 1 and 2
Number of subjects: 20
Study 9919319 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 27
Study 9919319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8789310 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy with omeprazole, bismuth, tetracycline and metronidazole for 1 week (pretreated with omeprazole for 3 days)
Number of subjects: 76
Study 8789310 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with omeprazole and amoxicillin for 2 weeks
Number of subjects: 76
Study 1872398 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded balloon distensions (1 min duration at 10-min intervals in 8-ml stepwise increments)
Number of subjects: 11
Study 1872398 — intervention group
Group type: EXPERIMENTAL
Intervention: Unperceived orad distensions
Number of subjects: 11
Study 1872398 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-cm-caudad distensions at higher levels
Number of subjects: 11
Study 7175837 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic fetal monitoring
Number of subjects: 690
Study 7175837 — intervention group
Group type: COMPARATOR
Intervention: Auscultation alone
Number of subjects: 690
Study 7175837 — intervention group
Group type: COMPARATOR
Intervention: Electronic fetal monitoring with scalp pH sample option
Number of subjects: 690
Study 7175837 — intervention group
Group type: COMPARATOR
Intervention: Cesarean section
Number of subjects: 690
Study 7175837 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged hours of internal catheter usage greater than 8 hours
Number of subjects: 690
Study 7175837 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged rupture of membranes greater than 12 hours
Number of subjects: 690
Study 30322847 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (CPB) at 35°C‐36°C
Number of subjects: 200
Study 27396580 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band-based high-speed power training (HSPT)
Number of subjects: 30
Study 27396580 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-speed strength training (LSST)
Number of subjects: 30
Study 27396580 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 30
Study 26053350 — intervention group
Group type: EXPERIMENTAL
Intervention: More Fun with Sisters and Brothers program (MFWSB)
Number of subjects: 84
Study 26053350 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 84
Study 23413014 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with TAXUS Express paclitaxel‐eluting stents
Number of subjects: 1800
Study 23413014 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1800
Study 21332375 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-graded exposure therapy (VR-GET)
Number of subjects: 19